Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
LAVOLTA (L) I & II were randomized, double-blind, Phase 3 trials of lebrikizumab (LEB), a humanized monoclonal antibody targeting IL-13, in adults with uncontrolled asthma (LI, NCT01867125, and LII, NCT01868061). These studies enrolled patients irrespective of asthma exacerbation history. Recent studies of biologic medications in severe asthma have shown that exacerbation history and baseline eosinophilia impact outcomes.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
